Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, medical device company AngioDynamics (ANGO +5.01%) has earned a coveted five-star ranking.
With that in mind, let's take a closer look at AngioDynamics and see what CAPS investors are saying about the stock right now.
AngioDynamics facts
|
Headquarters (founded) |
Latham, N.Y. (1988) |
|
Market Cap |
$354.3 million |
|
Industry |
Health care equipment |
|
Trailing-12-Month Revenue |
$250.8 million |
|
Management |
CEO Joseph DeVivo (since 2011) |
|
Return on Equity (average, past 3 years) |
1.2% |
|
Cash/Debt |
$30.5 million / $149.2 million |
|
Competitors |
Boston Scientific (NYSE: BSX) |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 86% of the 110 members who have rated AngioDynamics believe the stock will outperform the S&P 500 going forward.
Earlier this week, one of those Fools, ScalaAnalyst, succinctly summed up the AngioDynamics bull case for our community:
This is a nice small company that seems to do well competing against larger companies. Their growth rates the last few years along with their quarters show that company is going to stay with us for a while. ... Also the price to book ratio is also quite low. Altogether a good stock for the next year or three.
If you want market-thumping returns, you need to put together the best portfolio you can. Of course, despite a perfect five-star rating, AngioDynamics may not be your top choice.
We've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
